Gi-Young Sohn
Chief Executive Officer chez ENZYCHEM LIFESCIENCES CORPORATION
Fortune : 6 M $ au 31/03/2024
Profil
Gi-Young Sohn is currently the Chief Executive Officer & Director at ENZYCHEM LIFESCIENCES Corp.
since 2012.
He is also the Chairman at Bridget Lifesciences Corp.
since 2003.
Mr. Sohn has an undergraduate and graduate degree from Korea University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 07/05/2024 | 4 069 430 ( 4,78% ) | 6 M $ | 31/03/2024 |
Postes actifs de Gi-Young Sohn
| Sociétés | Poste | Début |
|---|---|---|
| ENZYCHEM LIFESCIENCES CORPORATION | Chief Executive Officer | 01/06/2012 |
Bridget Lifesciences Corp.
 Bridget Lifesciences Corp. Financial ConglomeratesFinance Bridget Lifesciences Corp. functions as an investment holding South Korean company. Hye-Kyung Kim has been the CEO of the private company since 2003. | Chairman | 01/01/2003 |
Formation de Gi-Young Sohn
| Korea University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENZYCHEM LIFESCIENCES CORPORATION | Health Technology |
| Entreprise privées | 1 |
|---|---|
Bridget Lifesciences Corp.
Bridget Lifesciences Corp. Financial ConglomeratesFinance Bridget Lifesciences Corp. functions as an investment holding South Korean company. Hye-Kyung Kim has been the CEO of the private company since 2003. | Finance |
